Ropes & Gray Advised Sanofi In Acquisition Of Dren Bio’s Deep B-Cell Depleter Program
Ropes & Gray Advised Sanofi In Acquisition Of Dren Bio’s Deep B-Cell Depleter Program
The deal was worth to $1.9 billion
American multinational law firm Ropes & Gray has advised Sanofi to acquire Dren Bio’s deep B-cell depleter program, DR-0201.
The bispecific myeloid cell engager has the potential to reset the adaptive immune system. It could lead to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases. These include lupus, where significant unmet medical needs exist.
Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate Dren-0201 for a payment of $600 million and future payments of $1.3 billion.
The transaction is expected to close in the second quarter of 2025.
The Ropes & Gray team was led by life sciences licensing Partner Abigail Gregor, Mergers & Acquisitions Partner Matt Byron and IP transaction associate Dan Freshman.
The team included Tax Partner Scott Pinarchick, Employment & Benefits Partner Renata Ferrari and IP Transactions Counsel Joshua Talicska, Mergers & Acquisitions Associate Alexandra Charron and IP Transactions Associate Giancarlo Lee.
